Article citationsMore>>

Nambiar, D.K., Aguilera, T., Cao, H., Kwok, S., Kong, C., Bloomstein, J., et al. (2019) Galectin-1-Driven T Cell Exclusion in the Tumor Endothelium Promotes Immunotherapy Resistance. Journal of Clinical Investigation, 129, 5553-5567.
https://doi.org/10.1172/jci129025

has been cited by the following article:

• TITLE: Research Progress of Gal-1 and Gastric Cancer

  AUTHORS: Kaihai Jiang, Kun Dai, Xusen Huang

  KEYWORDS: Galectin-1, Gastric Cancer, Research Progress

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.3, March 14, 2025

  ABSTRACT: Gastric cancer (GC) is one of the most common cancers in the world and the leading cause of cancer-related death in China. At present, the intervention measures for GC are limited. Therefore, it is particularly important to find biological markers and targeted therapy for the occurrence and development of GC. Galectin-1 (Gal-1) is a member of the human lectin family and has attracted attention for its association with human tumor invasion behavior. Recent studies have found that the expression of Gal-1 in tumor cells is closely related to the migration, invasion and tumor-induced angiogenesis of tumor cells. This article reviews the research progress of Gal-1 in GC, which is helpful to discover the therapeutic effect of Gal-1 in GC diseases.